Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX–bevacizumab or FOLFIRI–bevacizumab: results …
…, AL Cohn, HI Hurwitz, M Kozloff, H Tezcan… - The …, 2012 - academic.oup.com
Background. The Avastin® Registry: Investigation of Effectiveness and Safety (ARIES) study
is a prospective, community-based observational cohort study that evaluated the …
is a prospective, community-based observational cohort study that evaluated the …
Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised …
…, V Holden, J Neidhart, M De Oliveira, H Tezcan… - The Lancet …, 2018 - thelancet.com
Background Initial results from the ongoing GALLIUM trial have shown that patients with
follicular lymphoma have a longer progression-free survival after first-line immunochemotherapy …
follicular lymphoma have a longer progression-free survival after first-line immunochemotherapy …
Early assessment of molecular progression and response by whole-genome circulating tumor DNA in advanced solid tumors
Abstract Treatment response assessment for patients with advanced solid tumors is complex
and existing methods require greater precision. Current guidelines rely on imaging, which …
and existing methods require greater precision. Current guidelines rely on imaging, which …
Validation of the 12-gene colon cancer recurrence score as a predictor of recurrence risk in stage II and III rectal cancer patients
…, M Lee, M Lopatin, H Tezcan… - Journal of the …, 2014 - academic.oup.com
Background The 12-gene Recurrence Score assay is a validated predictor of recurrence
risk in stage II and III colon cancer patients. We conducted a prospectively designed study to …
risk in stage II and III colon cancer patients. We conducted a prospectively designed study to …
[HTML][HTML] Impact of the 12-gene colon cancer assay on clinical decision making for adjuvant therapy in stage II colon cancer patients
…, M Mishaeli, S Man, L Soussan-Gutman, H Tezcan… - Value in health, 2016 - Elsevier
Objectives To evaluate the impact of the 12-gene Colon Cancer Recurrence Score Assay—a
clinically validated prognosticator in stage II colon cancer after surgical resection—on …
clinically validated prognosticator in stage II colon cancer after surgical resection—on …
Limited stage I and II follicular non-Hodgkin's lymphoma: the Nebraska Lymphoma Study Group experience
H Tezcan, JM Vose, M Bast, PJ Bierman… - Leukemia & …, 1999 - Taylor & Francis
The purpose of this study was to evaluate the outcome and prognostic factors of patients
with limited stage follicular non-Hodgkin's lymphoma treated prospectively by the Nebraska …
with limited stage follicular non-Hodgkin's lymphoma treated prospectively by the Nebraska …
Early detection of molecular disease progression by whole-genome circulating tumor DNA in advanced solid tumors
…, H Wood, J Close, A Tezcan, K Nesmith, H Tezcan… - medrxiv, 2019 - medrxiv.org
Purpose Treatment response assessment for patients with advanced solid tumors is complex
and existing methods of assessment require greater precision for early disease assessment…
and existing methods of assessment require greater precision for early disease assessment…
[PDF][PDF] İzmir Vizyonu ve Yönetişim
H Tezcan - içinde, 2007 - tepav.org.tr
Kentler yaşam alanlarının ötesinde bir anlama sahiptir. Artık ülkeler sahip olduğu kentsel
özellikleri ile kentlerin isimleri ile anılmaktadır. Tanınmanın ve kalıcı olmanın en etkin yolu da …
özellikleri ile kentlerin isimleri ile anılmaktadır. Tanınmanın ve kalıcı olmanın en etkin yolu da …
Prospective evaluation of a 12-gene assay on patient treatment decisions and physician confidence in mismatch repair-proficient (MMR-P) stage IIa colon cancer …
SR Alberts, LA Renfro, M Lopatin, H Tezcan, J Sloan… - 2014 - ascopubs.org
396 Background: The 12-gene Oncotype DXColon Cancer Assay is clinically validated as a
predictor of recurrence risk in stage II colon cancer patients following surgery. We previously …
predictor of recurrence risk in stage II colon cancer patients following surgery. We previously …
Analysis of tumor DNA in urine as a highly sensitive liquid biopsy for patients with non-muscle invasive bladder cancer (NMIBC)
…, RD Abramson, M Crager, M Bonham, H Tezcan… - Clinical Cancer …, 2016 - AACR
Noninvasive detection of urine tumor DNA (utDNA) has the potential to augment the
diagnosis and management of bladder cancer. We sought to identify whether patient specific …
diagnosis and management of bladder cancer. We sought to identify whether patient specific …